Back to search

France· FR:60663231

KINERET 100 mg/0,67 mL, solution injectable en seringue préremplie

A anakinra product containing anakinra, registered in France by SWEDISH ORPHAN BIOVITRUM INTERNATIONAL (SUEDE), on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.

Reimbursed in France (Assurance maladie)ATC L04AC03

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedKINERET 100 mg/0,67 mL, solution inje…ATCL04AC03REGISTER NO.FR:60663231PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Anakinra is registered in 13 of 19 countries.

Countries holding a registration under ATC L04AC03 (anakinra), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 8 of them publish a price we can compare per daily dose

Anakinra · ATC L04AC03

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
ANAKINRA
Manufacturer
SWEDISH ORPHAN BIOVITRUM INTERNATIONAL (SUEDE)
Country
France (FR)
ATC code
L04AC03
ATC class
Anakinra
Defined daily dose
0.1 g, P
Reimbursed
Yes
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • cip13
    3400927732034
    7 seringue(s) préremplie(s) en verre de 0,67 ml
    EUR 188.47

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

375 interactions on record for anakinra.

Graded by severity as the source publishes them — 31 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Anakinra · interactions on record

375 records

  • 31 severe
  • 337 moderate
  • 7 minor

Most severe, free to view

  • CladribineL01BB04severe
  • PrednisoloneA07EA01moderate
  • HydrocortisoneA07EA02moderate
  • PrednisoneA07EA03moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/91ff41b3-0e13-4693-a3e0-a65beb6a7ab3
GET /v1/drugs/91ff41b3-0e13-4693-a3e0-a65beb6a7ab3?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "60663231",
  "date_amm": "2013-11-15",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/02/203",
  "substance": "ANAKINRA",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "solution injectable",
  "voies_administration": "sous-cutanée",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}

See everything about anakinra.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.